141 related articles for article (PubMed ID: 35801736)
21. Effects of dacomitinib on the pharmacokinetics of poziotinib
Ji W; Shen J; Wang B; Chen F; Meng D; Wang S; Dai D; Zhou Y; Wang C; Zhou Q
Pharm Biol; 2021 Dec; 59(1):457-464. PubMed ID: 33899675
[TBL] [Abstract][Full Text] [Related]
22. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
[TBL] [Abstract][Full Text] [Related]
23. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
[TBL] [Abstract][Full Text] [Related]
24. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
Stättermayer AF; Halilbasic E; Wrba F; Ferenci P; Trauner M
J Hepatol; 2020 Sep; 73(3):651-663. PubMed ID: 32376413
[TBL] [Abstract][Full Text] [Related]
25. Endoscopic nasobiliary drainage: an effective treatment option for benign recurrent intrahepatic cholestasis (BRIC).
Choudhury A; Kulkarni AV; Sahoo B; Bihari C
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28476903
[TBL] [Abstract][Full Text] [Related]
26. Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib.
Han M; Zhang X; Ye Z; Wang J; Kong Q; Hu X; Qian J; Cai J; Hu G
Chem Res Toxicol; 2022 Feb; 35(2):265-274. PubMed ID: 34936353
[TBL] [Abstract][Full Text] [Related]
27. [Classic case of benign recurrent intrahepatic cholestasis (Summerskill-Halshe-Tygstrup syndrome)].
Westermann G; Lügering N; August C; Rahn KH; Kisters K
Med Klin (Munich); 2000 Jun; 95(6):349-54. PubMed ID: 10935421
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of 2 patients with brain metastases from non-small cell lung cancer with epidermal growth factor receptor mutation receiving dacomitinib: A case report.
Zhao S; Cong X; Liu Z
Medicine (Baltimore); 2021 Jul; 100(30):e26680. PubMed ID: 34397694
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.
Chen X; Jiang J; Giri N; Hu P
Xenobiotica; 2018 May; 48(5):459-466. PubMed ID: 28648122
[TBL] [Abstract][Full Text] [Related]
30. [Progressive familial intrahepatic cholestasis type 3].
Lipiński P; Jankowska I
Dev Period Med; 2018; 22(4):385-389. PubMed ID: 30636238
[TBL] [Abstract][Full Text] [Related]
31. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Kim DW; Garon EB; Jatoi A; Keefe DM; Lacouture ME; Sonis S; Gernhardt D; Wang T; Giri N; Doherty JP; Nadanaciva S; O'Connell J; Sbar E; Cho BC
Lung Cancer; 2017 Apr; 106():76-82. PubMed ID: 28285698
[TBL] [Abstract][Full Text] [Related]
32. [Mechanism of Cinnamomi Ramulus improving rat model of intrahepatic cholestasis induced by ANIT by regulating FXR pathway].
Cai X; Qin RW; Liu YQ; Wang Y; Luo L; Yang F
Zhongguo Zhong Yao Za Zhi; 2019 Jun; 44(12):2594-2599. PubMed ID: 31359729
[TBL] [Abstract][Full Text] [Related]
33. 'Intrahepatic cholestatic hepatitis following diagnostic ajmaline challenge'.
Mellor G; Fellows I; Williams I
Europace; 2013 Mar; 15(3):314. PubMed ID: 22804909
[No Abstract] [Full Text] [Related]
34. Vitamin A-induced cholestatic hepatitis: a case report.
Becker P; Maurer B; Schirmacher P; Waldherr R; Parlesak A; Bode C; Seitz HK
Z Gastroenterol; 2007 Oct; 45(10):1063-6. PubMed ID: 17924304
[TBL] [Abstract][Full Text] [Related]
35. Severe cholestatic hepatitis caused by azathioprine.
Eisenbach C; Goeggelmann C; Flechtenmacher C; Stremmel W; Encke J
Immunopharmacol Immunotoxicol; 2005; 27(1):77-83. PubMed ID: 15803861
[TBL] [Abstract][Full Text] [Related]
36. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer.
Mizusaki S; Otsubo K; Ninomiya T; Arimura H; Tsuchiya-Kawano Y; Inoue K
Thorac Cancer; 2021 Jan; 12(1):114-116. PubMed ID: 33112047
[TBL] [Abstract][Full Text] [Related]
37. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
[TBL] [Abstract][Full Text] [Related]
38. Progressive familial intrahepatic cholestasis type-3 and multiple sclerosis: lessons from comorbidity.
De Masi R; Orlando S; De Donno A
Ann Clin Transl Neurol; 2019 Nov; 6(11):2347-2350. PubMed ID: 31568708
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Giri N; Masters JC; Plotka A; Liang Y; Boutros T; Pardo P; O'Connell J; Bello C
Invest New Drugs; 2015 Aug; 33(4):931-41. PubMed ID: 26048096
[TBL] [Abstract][Full Text] [Related]
40. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.
Mallat A; Zafrani ES; Metreau JM; Dhumeaux D
Dig Dis Sci; 1997 Jul; 42(7):1486-8. PubMed ID: 9246051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
